OPKO Health, Inc. (OPK)’s ModeX Division Pushes Four Immuno-Oncology Candidates into Phase 1

Core Insights - OPKO Health, Inc. is a diversified healthcare company involved in diagnostics, pharmaceuticals, and innovative therapies, with a focus on immuno-oncology and metabolic disorders [1] - The company has seen significant insider buying in 2025, indicating strong confidence from key shareholders in its long-term prospects [2] Company Developments - CEO Phillip Frost, the largest shareholder with approximately 31% ownership, has participated in recent share purchases, increasing the top five holders' combined ownership to 51% [2] - OPKO is advancing a Phase 1 Epstein-Barr virus vaccine in collaboration with Merck, with potential Phase 2 trials starting next year [3] - The ModeX division is innovating in immuno-oncology with four candidates in the pipeline, including MDX2001, currently in Phase 1 trials [3] Product Pipeline - OPKO is addressing obesity through a collaboration with Entera Bio on OPK-88006, an oral dual GLP-1/glucagon agonist, with promising results presented at ENDO 2025 [4] - The company is developing both oral and injectable formulations to meet the increasing demand for obesity treatments [4] Financial Performance - OPKO reported Q2 2025 revenue of $156.8 million, a decline from the previous year, but is projected to achieve revenues of $640–$660 million for 2025 [5] - The recent sale of select oncology testing assets to Labcorp aims to streamline operations and improve liquidity [5] - The company is focusing on its pipeline, cost savings, and strategic divestitures to enhance margins and move towards profitability [5]